Fenini et al., 2017 - Google Patents
Potential of IL-1, IL-18 and inflammasome inhibition for the treatment of inflammatory skin diseasesFenini et al., 2017
View HTML- Document ID
- 6746585482615922145
- Author
- Fenini G
- Contassot E
- French L
- Publication year
- Publication venue
- Frontiers in pharmacology
External Links
Snippet
In 2002, intracellular protein complexes known as the inflammasomes were discovered and were shown to have a crucial role in the sensing of intracellular pathogen-and danger- associated molecular patterns (PAMPs and DAMPs). Activation of the inflammasomes …
- 108010034143 Inflammasomes 0 title abstract description 81
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Fenini et al. | Potential of IL-1, IL-18 and inflammasome inhibition for the treatment of inflammatory skin diseases | |
| Yabal et al. | Stressing out the mitochondria: Mechanistic insights into NLRP3 inflammasome activation | |
| Broderick et al. | The inflammasomes and autoinflammatory syndromes | |
| ES2346184T3 (en) | ANTAGONISTS OF CD30 OR CD30L FOR USE IN THE TREATMENT OF CHRONIC AND AUTOIMMUNE ANTI-INFLAMMATORY DISEASES. | |
| Othy et al. | Intravenous gammaglobulin inhibits encephalitogenic potential of pathogenic T cells and interferes with their trafficking to the central nervous system, implicating sphingosine-1 phosphate receptor 1–mammalian target of rapamycin axis | |
| Goh et al. | A novel human anti-interleukin-1β neutralizing monoclonal antibody showing in vivo efficacy | |
| JP6671069B2 (en) | Agent for preventing or treating inflammatory diseases | |
| de Koning et al. | Intracellular serine protease inhibitor SERPINB4 inhibits granzyme M-induced cell death | |
| Zoccal et al. | Ts6 and Ts2 from Tityus serrulatus venom induce inflammation by mechanisms dependent on lipid mediators and cytokine production | |
| Harel et al. | Balance between Interleukin-18 and Interleukin-18 binding protein in auto-inflammatory diseases | |
| JP2019511458A (en) | Recombinant IgG Fc Multimer | |
| US8580255B2 (en) | Method for the treatment of rheumatoid arthritis using a TLR2 antagonistic antibody | |
| Cardani et al. | Oral administration of interleukin-10 and anti-IL-1 antibody ameliorates experimental intestinal inflammation | |
| BR112020021269A2 (en) | ANTI-ROR ANTIBODY CONSTRUCTIONS | |
| CA3058427C (en) | Alt-803 in combination with anti-cd38 antibody for cancer therapies | |
| CA3091996A1 (en) | Inhibitors of pla2-g1b cofactors for treating cancer | |
| Hiramatsu et al. | Recombinant fusion protein of cholera toxin B subunit with YVAD secreted by Lactobacillus casei inhibits lipopolysaccharide-induced caspase-1 activation and subsequent IL-1 beta secretion in Caco-2 cells | |
| Rea et al. | Triple jeopardy in ageing: COVID-19, co-morbidities and inflamm-ageing | |
| Metzemaekers et al. | Fast and furious: The neutrophil and its armamentarium in health and disease | |
| CN111655289A (en) | Combination therapeutic agents | |
| WO2021062332A1 (en) | Combination of inhibitors of il4 signaling and immune checkpoints for treating cancer | |
| JP5954727B2 (en) | Carbonic anhydrase I as a novel antigen for the treatment of autoimmune diseases | |
| US10751416B2 (en) | IL-26 inhibitors | |
| Levin et al. | Modulating immunogenicity of factor IX by fusion to an immunoglobulin Fc domain: a study using a hemophilia B mouse model | |
| JP2017510577A (en) | Use of CD64 blocking agents as activators of anti-TNF-α antibody therapy |